Inotuzumab Ozogamicin: First Global Approval

Drugs

Volumn 77, Issue 14, 2017, Pages 1603-1610

  Lamb, Yvette N ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INOTUZUMAB OZOGAMICIN; ANTINEOPLASTIC AGENT; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE DRUG REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG CLEARANCE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; ELIMINATION HALF-LIFE; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; NAUSEA; NEUTROPENIA; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 3 CLINICAL TRIAL; PLASMA PROTEIN BINDING; THROMBOCYTOPENIA; UNITED STATES; VOLUME OF DISTRIBUTION; B CELL LYMPHOMA; COMBINATION DRUG THERAPY; FOOD AND DRUG ADMINISTRATION; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HUMANS; LYMPHOMA, B-CELL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIALIC ACID BINDING IG-LIKE LECTIN 2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85027892470     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0802-5     Document Type: Article

References (28)

1. Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425–34.
2. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253–61.
3. Pfizer. Besponsa approved in the EU for adult patients with relapsed or refractory B-cell percursor acute lymphoblastic leukemia [media release]. 30 Jun 2017. http://www.pfizer.com/.
4. Pfizer Limited. Besponsa (inotuzumab ozogamicin) 1 mg powder for concentrate for solution for infusion: summary of product characteristics. 2017. Accessed 21 Jul 2017.
5. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.
6. Wagner-Johnston ND, Goy A, Rodriguez MA, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(10):2863–9.
7. Goy A, Forero A, Wagner-Johnston N, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571–81.
8. European Medicines Agency. Summary of opinion (initial authorisation): Besponsa (inotuzumab ozogamicin). 2017. http://www.ema.europa.eu/. Accessed 21 Jul 2017.
9. Pfizer. Pfizer announces acceptance of regulatory submission for inotuzumab ozogamicin by the U.S. Food and Drug Administration [media release]. 21 Feb 2017. http://www.pfizer.com/.
10. Celltech Group Plc. Celltech Group plc oncology pipeline update [media release]. 16 Jun 2003. http://www.celltechgroup.com/.
11. Pfizer, Wyeth. Pfizer completes acquisition of Wyeth [media release]. 16 Oct 2009. http://www.pfizer.com/.
12. DiJoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67(4):741–9.
13. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14.
14. de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255–64.
15. DiJoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–5.
16. DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–80.
17. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387–98.
18. Garrett M, Ruiz-Garcia A, Parivar K, et al. Characterization of inotuzumab ozogamicin time-dependent clearance in relapsed/refractory acute lymphoblastic leukemia patients by nonlinear mixed-effects analysis [abstract no. PC-26]. Clin Pharmacol Ther. 2016;99(Suppl 1):S11.
19. Kebriaei P, DeAngelo DJ, Stelljes M, et al. Factors associated with allogeneic hematopoietic stem cell transplantation (HSCT) outcomes in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO) versus (v) conventional chemotherapy (C) [abstract no. 7007]. J Clin Oncol. 2017;35(15 Suppl):7007.
20. Kantarjian HM, Su Y, Jabbour EJ, et al. Patient-reported outcomes from a global phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard of care chemotherapy for relapsed/refractory acute lymphoblastic leukemia [abstract no. 1599]. Blood. 2016;128(22):1599.
21. van Oostrum I, Su Y, Heeg B, et al. Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) [abstract no. e18506]. J Clin Oncol. 2017;35(15 Suppl).
22. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11.
23. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36.
24. Rytting M, Triche L, Thomas D, et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(2):369–72.
25. Bhojwani D, Sposto R, Shah N, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) [abstract no. 10512]. J Clin Oncol. 2017;35(15 Suppl):10512.
26. Assi R, Kantarjian HM, Ravandi F, et al. Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL) [abstract no. 7025]. J Clin Oncol. 2017;35(15 Suppl):7025.
27. Sasaki K, Jabbour EJ, O’Brien SM, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial [abstract no. 588]. Blood. 2016;128(22):588.
28. Advani AS, Moseley A, Liedtke M, et al. A phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/refractory CD22+ acute leukemia (SWOG 1312) [abstract no. 1634]. Blood. 2016;128(22):1634.